Lantheus Holdings, Inc. (LNTH)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$500.3M
Cash & Equivalents
$125.1M
Quarterly Burn Rate
$6,878M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
FLORBETABEN F-18
NEURACEQ |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-13 | Pdufa | — |
| 2026-09-01 | Phase1 Readout | — |
| 2027-02-02 | Phase1 Readout | — |
| 2027-03-01 | Phase1 Readout | — |
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (15)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03493516 | Prediction of ARrhythmic Events With Positron Emission Tomography II | OTHER | Active Not Recruiting | 302 |
| NCT04286100 | Contrast Specific Echocardiogram Versus Left Ventricular Opacification (LVO) Imaging Settings | OTHER | Active Not Recruiting | 60 |
| NCT07335315 | Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disea... | OTHER | Recruiting | 110 |
| NCT06074510 | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer | PHASE4 | Active Not Recruiting | 274 |
| NCT05160480 | A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG | OTHER | Enrolling By Invitation | 9 |
| NCT05416385 | Carotid Intraplaque Neovascularization Combined With Stress Echo | OTHER | Recruiting | 1,500 |
| NCT03674255 | Echocardiography: Value and Accuracy at REst and STress | OTHER | Enrolling By Invitation | 23,000 |
| NCT05641688 | [18F]PI-2620 Phase 3 Histopathological Study | PHASE3 | Recruiting | 200 |
| NCT04557501 | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer | PHASE3 | Active Not Recruiting | 800 |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | PHASE2 | Recruiting | 26 |
| NCT07357519 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | PHASE2 | Recruiting | 55 |
| NCT03976843 | Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | PHASE2 | Active Not Recruiting | 175 |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocel... | PHASE1 | Recruiting | 36 |
| NCT06790394 | Test-retest Study With [18F]FBB in Cardiac Amyloidosis | PHASE1 | Recruiting | 15 |
| NCT07501650 | Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer | PHASE1 | Recruiting | 6 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.